Moderna Expands mRNA Vaccine Development Programs

Massachusetts-based Moderna, Inc. today announced that it is expanding its mRNA pipeline with two new development programs, including a combination respiratory vaccine candidate and a new program against all four of the endemic human coronaviruses (HCoV).

First, as part of Moderna's approach to advance a portfolio of respiratory candidates, it is launching a respiratory combination vaccine program to target three of the most significant viruses causing respiratory disease in older adults.

The new combination respiratory vaccine candidate (mRNA-1230) is envisioned as an annual booster targeting the SARS-CoV-2 coronavirus, influenza, and respiratory syncytial virus.

Second, Moderna introduced a program to develop a vaccine candidate (mRNA-1287) against endemic HCoVs.

While less well known than other coronaviruses, HCoVs are a significant cause of respiratory disease worldwide.

Four HCoVs (HCoV-229E, -NL63, -OC43, and -HKU1) are endemic globally, accounting for approximately 10% to 30% of upper respiratory tract infections in adults.

Stephen Hoge, M.D., President of Moderna, commented in a related press release issued on March 22, 2022, "Our goal is to develop vaccines to address respiratory infections, and eventually combine many into a single annual booster vaccine with the aim of reducing the significant morbidity and mortality caused by these viruses."

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology, and manufacturing. It has allowed the development of therapeutics and vaccines for immuno-oncology, infectious, rare, cardiovascular, and auto-immune diseases.

Moderna's lead product is the SpikeVax vaccine.

Note: Moderna's press statement was edited for clarity and manually curated for mobile readers.